Industry News

Hua'an Major products include Clinical Thermometer,Digital Thermometer,Ear Thermometer and Digital Blood Pressure Monitor etc.

« Atlantic: the pursuit of quality test and measurement technology advocate Fosun subsidiary of US-China mutually beneficial exchange of shares »

Fosun a joint venture with the United States in the new company benefits

    Mutually beneficial in a number of holdings, digital thermometer after the United States, Fosun Pharmaceutical relationship between the two sides of a grid up again.

    Fosun Medicine and Chindex December 28 signing in Shanghai,clinical thermometer announced that the two sides will jointly set up in Hong Kong a new joint venture company Chindex Medical Co., Ltd. (ChindexMedicalLtd.), both for the integration of its medical device (referred to as MPD) business. Among them, Fosun Pharmaceutical medical equipment into its existing business (except for medical diagnostic services),ear thermometer accounting for 51% stake in the joint venture, the United States and all of the MPD into mutually beneficial business,digital blood pressure monitor accounting for 49% equity joint venture.

    Fosun Chairman Chen Chi-yu said that Fosun brand of medicine and the combination of the United States is mutually beneficial international development strategy Fosun Pharmaceutical another milestone, but also Fosun strengthen "integrated endogenous development" an important symbol. The new company will be the future of both business optimization and integration of medical devices, medical devices to Fosun scale of operations will rise to a new level, improve the medical device sector Fosun Pharmaceutical R & D, manufacturing to domestic and international marketing of the industrial chain .

    According to China Economic Net report, after Fosun Pharmaceutical signed with the United States and benefit the "Stock Purchase Agreement" and "shareholder agreement" will benefit the United States in two conditional price of 15 dollars a share placement to Fosun A total of 1,990,447 shares of Class A common shares after the completion of additional Fosun Pharmaceutical benefit the United States may be held up to 25% stake. This joint venture benefits the United States after the second time to meet the additional conditions to Fosun benefit the United States in the 25% stake to the successful completion of mutually beneficial projects throughout the United States and all transactions to achieve their strategic alliance cooperation.

    Chindex for the Chinese market is a healthcare services and supplies medical equipment, medical and health of American companies. As the United States and mutually beneficial business of medical devices upgraded version of the joint venture will continue to sell the products of the large multinational companies, including Siemens imaging equipment and the da Vinci surgical robot, and Hologic, Candela, Cutera and other products. Joint venture will be the color Doppler ultrasound, mammography, cosmetic laser and surgical robot distribution partners, and will continue to hospitals in China for the purchase of medical equipment of the U.S. Export-Import Bank and the German KfW Development Bank loans. Meanwhile, as Fosun Pharmaceutical Medical Device business (except for clinical diagnostic products,) the successor to the joint venture will have a dental products and supplies, surgical suture products, medical supplies polymer manufacturing entity.

    Chindex RobertaLipson President and CEO, said: "We who have discussed the medical device business a variety of strategic choice, we believe that the establishment of a joint venture with Fosun more potential for development. Very happy to see a joint venture in the New Year the completion of the start. In our view, the business integration can complement each other, the size of a synergistic effect, so as to achieve the two sides can not alone achieve the effect of the operation. "

Post comment:

◎welcome to give out your point。

Calendar

Comments

Previous